Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.317
-0.014 (-4.11%)
At close: Dec 20, 2024, 4:00 PM
0.333
+0.016 (4.91%)
After-hours: Dec 20, 2024, 7:10 PM EST
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -90.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CYCC stock has a target of 11, which predicts an increase of 3,365.66% from the current stock price of 0.32.
Analyst Consensus: Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
The average analyst rating for CYCC stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $21 → $11 | Strong Buy | Maintains | $21 → $11 | +3,365.66% | May 3, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +6,516.26% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +37,707.18% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +37,707.18% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
54.06K
from 420.00K
Decreased by -87.13%
Revenue Next Year
102.00K
from 54.06K
Increased by 88.68%
EPS This Year
-1.99
from -26.75
EPS Next Year
-1.20
from -1.99
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 55,650 | 105,000 | 105,000 | |||
| Avg | 54,060 | 102,000 | 102,000 | |||
| Low | 51,940 | 98,000 | 98,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -86.8% | 94.2% | 2.9% | |||
| Avg | -87.1% | 88.7% | - | |||
| Low | -87.6% | 81.3% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.05 | -1.24 | -1.18 | |||
| Avg | -1.99 | -1.20 | -1.14 | |||
| Low | -1.91 | -1.16 | -1.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.